Sanctuary Advisors LLC Sells 1,439 Shares of LENSAR, Inc. (NASDAQ:LNSR)

Sanctuary Advisors LLC lessened its holdings in LENSAR, Inc. (NASDAQ:LNSR) by 7.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 19,181 shares of the company’s stock after selling 1,439 shares during the quarter. Sanctuary Advisors LLC owned approximately 0.17% of LENSAR worth $88,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of LNSR. Brandes Investment Partners LP boosted its stake in LENSAR by 12.8% in the second quarter. Brandes Investment Partners LP now owns 373,198 shares of the company’s stock valued at $1,644,000 after acquiring an additional 42,250 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of LENSAR by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock worth $460,000 after purchasing an additional 3,423 shares during the last quarter. Finally, DCF Advisers LLC boosted its position in shares of LENSAR by 1.4% in the 2nd quarter. DCF Advisers LLC now owns 241,484 shares of the company’s stock worth $1,087,000 after purchasing an additional 3,250 shares during the last quarter. Institutional investors and hedge funds own 40.15% of the company’s stock.

LENSAR Trading Up 3.3 %

NASDAQ LNSR opened at $8.66 on Tuesday. LENSAR, Inc. has a 12 month low of $2.67 and a 12 month high of $9.23. The stock has a 50-day simple moving average of $7.08 and a 200 day simple moving average of $5.50. The company has a market capitalization of $100.59 million, a PE ratio of -5.93 and a beta of 0.70.

About LENSAR

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.